Renaissance Technologies
CRDL

Renaissance Technologies’s Cardiol Therapeutics CRDL Stock Holding History

Renaissance Technologies’s Portfolio CRDL Stock Details CRDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$819K Buy
772,837
+543,031
+236% +$687K ﹤0.01% 2405
2026
Q1 		$310K Buy
+229,806
New +$236K ﹤0.01% 2781
2023
Q2 		– Sell
-10,100
Closed -$5K – 3971
2023
Q1 		$5K Buy
+10,100
New +$5.97K ﹤0.01% 3914
2022
Q1 		– Sell
-93,000
Closed -$171K – 4117
2021
Q4 		$171K Sell
93,000
-51,900
-36% -$143K ﹤0.01% 3566
2021
Q3 		$598K Buy
+144,900
New +$525K ﹤0.01% 2812

Other funds holding CRDL

MI
MMCAP International Grand Cayman, Cayman Islands $1.18B AUM 50.44% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $243M AUM 9.84% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
IA
Integrity Alliance Urbandale, Iowa $3.2B AUM 23.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
PAM
PVG Asset Management Golden, Colorado $173M AUM 64.51% 1-Year Est. Return

Renaissance Technologies's CRDL Position: Q2 2026 in Review

Renaissance Technologies increased its Cardiol Therapeutics (CRDL) stake by 236% in Q2 2026, buying an estimated $687K and bringing the position to 772,837 shares worth $819K. The position accounts for ﹤0.01% of the portfolio, ranked #2405.

Renaissance Technologies first reported a position in CRDL in Q3 2021 and has held it in 5 quarters since. 52 funds tracked by Wall St. Rank hold CRDL as of Q2 2026.

  • Renaissance Technologies held 772,837 shares of Cardiol Therapeutics worth $819K as of Q2 2026.
  • Renaissance Technologies bought 543,031 Cardiol Therapeutics shares in Q2 2026, an estimated $687K.
  • Cardiol Therapeutics made up ﹤0.01% of Renaissance Technologies's portfolio in Q2 2026, its #2405 holding.
  • Renaissance Technologies first reported a position in Cardiol Therapeutics in Q3 2021 and has held it in 5 quarters since.
  • 52 funds tracked by Wall St. Rank held Cardiol Therapeutics as of Q2 2026.

Based on Renaissance Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.